Introduction
Platelets express ABH antigens on several platelet glycolipids and glycoproteins, such as glycoprotein (GP) IIb/IIIa, GPIb/IX and CD109 [1] [2] [3] . Earlier studies suggested that ABH-active glycolipids are of extrinsic origin (i.e., absorbed from plasma) [4, 5] . More recent data indicate that they are mainly endogenous, as ABH-active glycolipids can also be found on platelets from Le (a+b-) individuals who lack plasma ABH glycosphingolipids [6] . The A antigen can be clearly detected in donors of the A 1 phenotype, while A 2 individuals carry little to no A antigen on their platelet surfaces [7] . However, even among A 1 individuals, antigen expression varies greatly from one individual to the next. Thus, A 1 donors can be classified into low or high expressers [8] . The frequency of the highexpresser phenomenon in an A 1 population is about 2-7% [8, 9] .
Antigen density on platelets and donor isoagglutinin concentration in the associated plasma may become clinically relevant when platelets are transfused across blood group barriers. However, the transfusion of ABO-incompatible platelets is common [10] . The ABO incompatibility was considered of minor concern regarding transfusion efficacy, but ABO incompatibility can be responsible for lower platelet count increments, decreased platelet function and risk of platelet refractoriness, followed by higher rates of alloimmunization [10] [11] [12] [13] [14] . Further, hemolytic transfusion reactions may occur with ABO-minor-incompatible transfusions [3, 10, 15] . Although severe complications from the latter seem rare, mild to moderate hemolysis may be underreported [16] .
To date, only few investigations related the genotype with the level of expression of the blood group A on platelets [17] . We therefore examined the role of platelet donors' ABO genotype on platelet A antigen surface density and on the isoagglutinin concentration.
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Summary Background: The extent of expression of the blood group A on platelets is controversial. Further, the relation between platelets' blood group A expression and the titers of isoagglutinins has not been thoroughly investigated, so far. Methods: We evaluated the relation between the genotype with platelets' blood group A and H expression estimated by flow cytometry and the titers of isoagglutinins. Results: The A expression varied between genotypes and within genotypes. However, the expression in A 1 was stronger than in all other genotypes (p < 0.0001). An overlap of expression levels was apparent between homozygous A 1 A 1 and heterozygous A 1 individuals. Still, The A 1 A 1 genotype is associated with a particularly high antigen expression (p = 0.009). Platelets' A expression in A 2 versus blood group O donors was also significant (p = 0.007), but there was again an overlap of expression. The secretor status had only little influence on the expression (p = 0.18). Also, isoagglutinin titers were not associated with genotypes. Conclusion: To distinguish between A 1 and A 2 donors may reduce incompatible platelet transfusions and therefore be favorable on platelet transfusion increment. Clinical data are needed to support this notion.
Material and Methods
Donor Population
The study was approved by the Ethics Committee of the Medical University of Vienna, and informed consent was obtained from all participants. We obtained platelet aliquots from subsequent donations from 103 group A apheresis donors at the Department of Blood Group Serology and Transfusion Medicine at Vienna General Hospital, and the Viennese Red Cross. Samples of 32 group O apheresis donors served as negative controls for flow cytometry testing. Aliquots from whole blood samples were used for Lewis determinations and genotyping, and for the determination of levels of isoagglutinins.
Detection of ABH Expression by Flow Cytometry
Optimal conditions were found by titration experiments. We contrasted different cell counts, antibody concentrations, and washed versus unwashed platelets to achieve a display of a clear-cut platelet population on the flow cytometer. Based on the results from these experiments, the reagents were used as follows: i) anti-A reagent (BRIC 145 phycoerythrin(PE)-labeled; IBGRL Research Products, Bristol, UK), diluted 1: 8 in phosphate-buffered saline (PBS) according to the manufacturer's instructions, and further diluted 1: 2 in PBS, ii) anti-B reagent (BGRL 1 PE-labeled; IBGRL Research Products), diluted 1: 2 from a 1: 10 dilution in PBS, iii) anti-H reagent (BRIC 198 PE-labelled, IBGRL Research Products), diluted 1: 2 from a 1: 10 PBS dilution. Testing washed and unwashed platelets yielded similar results; therefore, we used unwashed platelets only.
A platelet aliquot was obtained from each concentrate about 1 h after apheresis when concentrates have rested for 1 h. Concentrates contained 35 or 44% plasma and 65 or 56% platelet additive solution (MacoPharma, Mouvaux, France). The median volume was 405 ml (range 250-505 ml), the platelet concentration was median 1,604 × 10 3 /µl (range 668-2,700 × 10 3 /µl). Aliquots were suspended in PBS, resulting in 2 × 10 5 platelets/ml. 2 µl of this platelet suspension were subsequently pipetted into five test tubes, each holding 18 µl HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and 5 µl allophycocyanin (APC)-labeled anti-CD41a (as a platelet marker, clone HIP8; Becton Dickinson (BD) Pharmingen, San Diego, CA, USA), in a total reaction volume of 25 µl. Subsequently, 10 µl of the respective ABH antibodies were added to the test tubes. Samples were stained with the anti-A antibodies (1: 8, or 1: 16 dilution, the latter, to confirm an approximate 50% drop in fluorescence intensity), anti-B antibodies as a negative control, anti-H antibodies, and an isotype control. After incubation in the dark at room temperature for 20 min, samples were resuspended in 500 µl HEPES-buffered paraformaldehyde.
Flow cytometry analyses were performed on a FACSCalibur flow cytometer (BD) equipped with a 488 nm argon laser. CaliBRITE beads (BD) were used to adjust instrument settings and compensate overlaps in fluorescence expected with the use of PE and APC fluorochromes. Forward scatter versus side scatter and versus fluorescence gates were set. A total of 10,000 events per sample were gated and analyzed. Data were recorded as the mean fluorescence intensity (MFI). To standardize quantification of fluorescence intensity, BD QuantiBRITE TM PE beads (BD) were run with each batch of samples, to allow the conversion of MFI values to antibodies bound per cell (ABPC) using known PE-to-antibodies ratios.
Donor Isoagglutinin Concentration
Donor anti-B titer was determined by the glass plate method, the result being the reciprocal of the highest dilution at which macroscopic agglutination occurred.
Genotyping ABO genotyping was based on SSP-PCR as previously published [18, 19] . Primers for A 1 , non-A 1 , A 2 , non-A 2 , O 1 , non-O 1 , O 2 , non-O 2 , B, and non-B were obtained from MWG-Biotech (Ebersberg, Germany). 5 µl of the appropriate primer mixes were pipetted into PCR tube strips. 5 µl of a PCR master mix containing PCR buffer, MgCl 2 , distilled water, a dNTP mix, Taq polymerase, and the respective DNA of the donor were then added for a total amplification volume of 10 µl. Following DNA denaturation at 94 ° C for 2 min, 10 cycles were run consisting of 94 ° C for 20 s and 65 ° C for 60 s, succeeded by 20 cycles consisting of 94 ° C for 20 s, 61 ° C for 60 s, and 72 ° C for 30 s.
Lewis blood group typing was performed using the DiaClon Anti-Le a and Anti-Le b ID-cards (Bio-Rad Laboratories, Hercules, CA, USA). The secretor status was further determined for Le (a-b-) individuals, using an allele-specific PCR protocol. The Se/se genotype was determined by the 428G>A and 571C>T nucleotide polymorphisms of the α1,2-L-fucosyltransferase 2 gene (FUT2) with primers 5ʹ-GCTACCCCTGCTCCTG-3ʹ and 5ʹ-CTGTTACTTGCAGCC-CAACG-3ʹ (428G)or 5ʹ-TAGGGGTCCATGTTCGCC-3ʹ and 5ʹ-CTGT-TACTTGCAGCCCAACG-3ʹ (571C). The Le/le genotype, coded by the α1,3/4-L-fucosyltransferase 3 gene (FUT3), was determined by typing for 202T>C polymorphism using the allele specific reverse primers 5ʹ-GTGGAAAGGCCAT-GTTCA-3ʹ (202T) and 5ʹ-GTGGAAAGGCCATGTTCG-3ʹ (202C) and 5ʹ-TTACCTGCAAAACCCAGTCC-3ʹ as the common forward primer. The 59T>G nucleotide polymorphism was determined by the allele-specific forward primers 5ʹ-CGCTGTCTGGCCGCTCG-3ʹ (59T) and 5ʹ-CGCTGTCTGGC-CGCTCT-3ʹ (59G) and a common reverse primer 5ʹ-TCGTAGTTGCTTCT-GCTGGG-3ʹ. The PCR-products were separated by agarose gel electrophoresis and subsequently visualized via UV transillumination. figure 1 . A wide range of A antigen densities among A donors is apparent ( fig. 2) . Values from 12 samples were as low as the background fluorescence detected on group O platelets (these were A 2 O 1 n = 10; A 1 A 2 n = 1; A 1 O 1 n = 1). These results were reproducible when testing platelets, which were collected from a different apheresis donation from the same donor (data not shown). A high expresser status, defined as antigen levels exceeding the mean by more than 2 times the standard deviation, was seen in 3 individuals (3%). Their histograms showed a shift to the right with a sharp peak ( fig. 1) , defining them as type-II high expressers (type-I high expressers presenting histograms similar to those of normal expressing A 1 individuals, but shifted towards higher MFI values) [7] . Differences between the A 1 and A 2 population were significant (p < 0.0001). When comparing the flow cytometry results of A 1 donors grouped by their four genotypes, significant differences among subgroups were also observed ( fig. 2 ). An overlap of ABPC levels is apparent between homozygous A 1 A 1 and heterozygous A 1 individuals. Still, The A 1 A 1 genotype is associated with a particularly high antigen expression (p = 0.009). Of note, the 3 individuals that classified as high A antigen expressers were all of the A 1 A 1 genotype. Levels of platelet expression of the A antigen from A 1 O 1 donors were not related to the plasma volume in the platelet concentrate (p > 0.05).
Statistical Analysis
The Correlation of Antigen Expression Using Two Different Concentrations of Anti-A Antibody
As described above, platelets were tested for their A antigen expression using two different concentrations of the anti-A antibody: a concentrated version according to manufacturer's instructions and a 1: 2 dilution thereof. An approximate 50% drop in MFI values across all samples was seen. There was positive correlation between the two series of antibody concentrations (r = 0.97; p < 0.0001), indicating that no prozone phenomenon due to an excess of antibodies or antigens interfered with the data and that using saturated antibody concentrations were not a prerequisite for the results of the study.
A Antigen Density of Platelets from A 2 versus Those from Blood Group O Donors
Several A 2 donors showed an antigen density on their platelets that exceeded the background fluorescence recorded on O platelets, and differences between these two populations were significant (p = 0.007) ( fig. 3) . Our results included one outlier, whose anti-A values exceeded the population's mean for A 2 donors almost 2.5 times (1,056 mean antibodies bound per cell versus 421.71 mean antibodies bound per cell of the A 2 donors). This donor was genotyped A 2 A 2 (the only A2A2 individual in our study population).
The Expression of H-Antigen Was Directly Associated with the A Genotype
Like A antigen expression, H antigen expression was also associated with the donor genotype (table 1, p < 0.001). As expected, A 2 individuals expressed more H antigen on their platelets than A 1 donors, and H antigen density was particularly low in A 1 A 1 donors. We also determined an H-to-A ratio, as recently published by DeLelys et al. [17] . Correspondingly, we found ratios to be lowest in A 1 A 1 donors, followed by A 1 O 2 < A 1 O 1 < A 1 A 2 < A 2 A 2 < A 2 O 1 .
The Influence of the Secretor Status on Platelets' Blood Group A Expression
The secretor status was assigned to 78 individuals. The presence of the secretor status did not influence the A antigen expression (fig. 4 , p = 0.067). To rule out skewed results in smaller genotype groups, we evaluated separately the expression in the largest group. However, also in A 1 O 1 donors the expression of A was not associated with the secretor status (p = 0.507). However, higher MFI values tended to be scored by samples from donors of the secretor status, an observation that included the three high-expresser individuals in the study population. 
Donors' Isotiter
We determined the anti-B isoagglutinin concentration in 103 group A apheresis donors ( fig. 5) . The median isotiter for the entire study population was 1: 8. The lowest titer was 1: 2, the highest titer was 1: 128 -the latter in an A 2 O 1 donor. Anti-B titers were not different among donors grouped according to their genotype (p = 0.627). Also, the three high expressers of the A antigen had similar anti-B titers as the other donors (p = 0.628).
Discussion
We showed the close association of the blood group A genotype with the quantity of the A antigen expressed on apheresis platelets. Thereby, the presence of an A 1 allele had the greatest influence on levels of the A antigen density. However, the mean for ABPC within the A 1 donors varied considerably, depending on their status of zygosity. The isoagglutinin titer was not associated with the blood group A genotype.
We quantified the A antigen expression converting the MFI values to ABPC through the use of BD QuantiBRITE PE beads. Thereby, the anti-A antibody was used in two different concentrations, one just 50% of the more concentrated one. This procedure allowed us to exclude a prozone phenomenon, or an underestimation of the antigen expression. In accordance with previously published studies [6] [7] [8] [9] , we showed that the presence of an A 1 allele had the greatest impact on A-antigen density. An about tenfold increased difference of A antigen expression was discernible between platelets from A 1 and A 2 donors. However, even among A 1 platelets the antigen expression varied considerably. Platelets from homozygous A 1 individuals expressed by far more A antigen than those from A 1 A 2 , A 1 O 2 or A 1 O 1 donors. This is further substantiated by our findings that all 3 high expressers of the A antigen were typed A 1 A 1 . Various factors leading to the high expresser phenotype have been discussed. Ogasawara et al. [8] observed an increased serum glycosyl transferase activity in group B high expressers, and similar findings were made by Curtis et al. [7] , who reported a 12.6-fold increase in type-II high expressers. A mutation leading to a gain of function in the mature protein has been discussed; however, sequencing studies have shown no differences to reported normal gene sequences [7] . Mutations in the FUT1 or FUT2 gene, resulting in larger quantities of H antigen available for conversion to A antigen have also been debated, but no effective polymorphisms were detected [9] . An autosomal dominant trait was discussed, but mechanisms of inheritance have yet to be defined, as are its molecular origins [7] [8] [9] .
While it has been established that group A 2 platelets carry considerably less A antigen than those of an A 1 phenotype [3, 6, 7, 9] , their differentiation from group O platelets by flow-cytometric analyses were inconclusive. Cooling et al. [6] suggested that A 2 platelets possess a Bombay-like phenotype, lacking both A and H antigen. Curtis et al. [7] found that A 2 platelets could not be differentiated from O platelets via flow cytometry. Sant'Anna Gomes et al. [9] and DeLelys et al. [17] described clear differences, however. In our study, 12 samples scored anti-A MFI values similar to a group O donor, 10 of these were even A 1 donors.
We see a clear association of the H antigen expression with the genotype. Recently, it was reported that this association becomes even more apparent, when H-to-A antigen ratios are calculated [17] . Our data are in line with the previous report showing a correlation between the A and H antigen in A 1 A 1 donors, but not in A 1 O donors (data not shown). An impact of ABO mismatching on transfusion efficacy in terms of lower platelet count increments has been described [14, 15, 23] . Yet, only a few studies have focused in endpoints such as patient survival or bleeding rates. Triulzi et al. [13] found no impact of ABO matching on the prevention of clinical bleeding, and only a small effect on transfusion intervals. Blumberg et al. [24] reported an association of ABO-incompatible platelet transfusions with an increase in morbidity and mortality in cardiac surgery patients. Others, however, found no such an association [25] . Shehata et al. [26] emphasized the need of studies on the effects of ABO matching on patient outcomes such as survival and bleeding rates.
We also determined isoagglutinin concentrations as they can trigger hemolytic transfusion reactions after ABO-minor-incompatible transfusions. [3, 10, 15, 27] . Our data indicate that the concentration of isoagglutinins is not associated with the A genotype. Reported hemolytic transfusion reactions usually involve group O donors [28] , but Daniel-Johnson et al. [29] also observed two severe hemolytic transfusion reactions by a high anti-B titer from a group A donor. Currently, however, there is no consensus cut-off for a 'dangerous' titer [30] . Further, antibody titers alone might not be sufficient to predict the risk of developing hemolysis after a minor-incompatible transfusion [31] . Furthermore, nowadays platelet concentrates may contain only small amounts of plasma, as the major part is substituted with platelet additive solutions.
Limitations of our study are the small sample size of certain genotypes (our study included only 1 A 2 A 2 genotype). Second, a trend towards higher antigen density in secretor status-positive individuals may have been influenced by the naturally occurring high percentage of secretors in the Caucasian population. Third, we prepared samples for flow cytometry testing soon after apheresis, but antigen expression may differ after prolonged storage [32] . Finally, we have no clinical outcome data.
In summary, we have shown that platelets from an A 1 genotype express significantly more A antigen on their platelets than A 2 platelets and that A antigen expression is strongest in individuals of the A 1 A 1 genotype, possibly rendering them less suitable for out-ofgroup platelet transfusions. Since we observed no differences in isoagglutinin concentrations between the genotypes, the genotype does not predict the risk of hemolytic transfusion reactions. Distinguishing between A 1 and A 2 donors could be a practical approach in reducing the risks associated with incompatible platelet transfusions.
